Related Experiment Videos
Liposomes modified with cyclic RGD peptide for tumor targeting
Praveen K Dubey1, Vivek Mishra, Sanyog Jain
1Drug Delivery Research Laboratory, Department of Pharmaceutical Sciences, Dr. Harisngh Gour University, Sagar, India.
Journal of Drug Targeting
|October 30, 2004
Summary
Cyclic RGD peptide anchored liposomes demonstrate enhanced targeting of angiogenic endothelial cells, significantly reducing tumor growth and metastasis in preclinical models. These targeted liposomes show promise for cancer chemotherapy.
Area of Science:
- Nanomedicine
- Drug Delivery
- Oncology
Background:
- Angiogenic endothelial cells overexpressing alphavbeta3 integrins are key targets in tumor tissue.
- Sterically stabilized liposomes offer a versatile platform for targeted drug delivery.
Purpose of the Study:
- To investigate the targeting potential of cyclic RGD peptide anchored sterically stabilized liposomes (RGD-SL) for cancer therapy.
- To evaluate the efficacy of RGD-SL loaded with 5-fluorouracil (5-FU) against primary tumors and metastasis.
Main Methods:
- Liposomes were prepared using distearoylphosphatidylcholine (DSPC), cholesterol, and DSPE-PEG-RGD conjugate.
- In vitro binding assays with HUVEC cells and in vivo metastasis and angiogenesis assays were performed.
- Therapeutic efficacy was assessed in B16F10 tumor-bearing mice treated with 5-FU loaded RGD-SL.
Main Results:
- RGD-SL exhibited a 7-fold higher binding affinity to HUVEC cells compared to control liposomes.
- RGD-SL significantly inhibited lung metastasis and angiogenesis (p<0.01).
- RGD-SL demonstrated effective tumor regression in vivo compared to free 5-FU and non-targeted liposomes.
Conclusions:
- Cyclic RGD peptide anchored liposomes effectively target tumor neovasculature.
- RGD-SL loaded with 5-FU show significant therapeutic potential against primary tumors and metastasis.
- Targeted liposomes represent a promising strategy for advanced cancer chemotherapeutics.